원바이오젠
Financials
Valuation Metrics
원바이오젠's Market Cap is ₩426B. At end of 2025 it was ₩474B. Ranked #1879 of 2,421 in KR market (top 78%), #1164 of 1,640 on KOSDAQ (top 71%), #78 of 96 in Health Care Equipment & Services (top 81%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 42.57B KRW | KR#1,879/2,421 Sec#78/96 |
| Revenue | 37.80B KRW | KR#1,944/2,421 Sec#59/96 |
| Net Income | 8.42B KRW | KR#1,029/2,421 Sec#29/96 |
| Total Assets | 53.88B KRW | KR#2,177/2,421 Sec#72/96 |
| Net Assets | 44.67B KRW | KR#1,980/2,421 Sec#65/96 |
| Employees | 72 | KR#1,861/2,421 Sec#74/96 |
| Value | ||
| P/E | 5.05x | KR#356/2,421 Sec#7/96 |
| P/B | 0.95x | KR#1,422/2,421 Sec#36/96 |
| PEG | 0.01x | KR#119/2,421 Sec#5/96 |
| P/S | 1.13x | KR#1,454/2,421 Sec#33/96 |
| EV/EBITDA | 4.68x | KR#204/2,421 Sec#6/96 |
| FCF Yield | 15.30% | KR#433/2,421 Sec#7/96 |
| Profitability | ||
| ROE | 18.85% | KR#196/2,421 Sec#7/96 |
| ROA | 15.63% | KR#108/2,421 Sec#7/96 |
| Op. Margin | 24.86% | KR#98/2,421 Sec#7/96 |
| Revenue Growth | 18.04% | KR#604/2,421 Sec#33/96 |
| Earnings Growth | 433.53% | KR#122/2,421 Sec#5/96 |
| Financial Health | ||
| Debt Ratio | 20.61% | KR#381/2,421 Sec#20/96 |
| Total Debt | 5.50B KRW | KR#1,774/2,421 Sec#65/96 |
| FCF | 6.51B KRW | KR#835/2,421 Sec#23/96 |
| Cash | 4.07B KRW | KR#2,082/2,421 Sec#82/96 |
| Current Ratio | 3.25x | KR#509/2,421 Sec#32/96 |
| Net Debt/EBITDA | 0.15x | KR#623/2,421 Sec#25/96 |
| Dividend | ||
| Div. Yield | 2.35% | KR#792/2,421 Sec#18/96 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/96 |
| Performance | ||
| 1Y Return | 8.30% | KR#587/2,421 Sec#13/96 |
| 1M Return | -2.91% | KR#1,579/2,421 Sec#51/96 |
| From 52W High | -28.57% | KR#489/2,421 Sec#13/96 |
| 1Y MDD | -37.33% | KR#482/2,421 Sec#11/96 |
| Trading | ||
| Volume | 7,843 shares | KR#2,014/2,421 Sec#82/96 |
| Trading Value | 46.8M KRW | KR#1,855/2,421 Sec#72/96 |
| Foreign Own. | 2.56% | KR#1,434/2,421 Sec#52/96 |
| Per Share | ||
| EPS | 1,187 KRW | KR#651/2,421 Sec#14/96 |
| BPS | 6,297 KRW | KR#1,319/2,421 Sec#31/96 |
Company Info
The company, established in 2006, was listed on the KOSDAQ market in 2021 through a reverse merger with Kyobo 8th Special Purpose Acquisition Company. It manufactures medical materials, wound dressings, biosensor patches, and cosmetics, primarily supplying polyurethane foam dressings and hydrocolloid dressings to hospitals and pharmacies. Driven by population aging and increasing plastic surgeries, the company is expanding its business into the wound dressing market and developing skin regeneration and functional cosmetics in the derma-cosmetic sector. WonBiogen was established in 2018 and is headquartered in Gumi-si, Gyeongsangbuk-do.